- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01111981
Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia
Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in the Treatment of Central Centrifugal Cicatricial Alopecia
The purpose of this study is to ascertain the safety and efficacy of
Clobetasol Propionate 0.05% E Foam in the treatment of Central Centrifugal
Cicatricial Alopecia.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Central Centrifugal Cicatricial Alopecia (CCCA) is an inflammation-induced
hair loss starting in the central scalp and progressing centrifugally. The
cause of CCCA is unknown. Early diagnosis and treatment is essential to stop
or slow the progression of scarring and permanent hair loss. Once scarring
occurs, the hair follicles are obliterated and the hair cannot regrow. Thus,
anti-inflammatory medications are used to decrease inflammation. Current
treatment includes topical and intralesional corticosteroids, oral
antibiotics, and hair transplantation, all which may take months to years to
show improvement. There is no evidence-based medicine on how to treat
primary cicatricial alopecias. Clobestasol Propionate 0.05% Emollient Foam is
an FDA-approved and marketed topical corticosteroid for the treatment of the
inflammatory and pruritic manifestations of moderate to severe corticosteroid-
responsive dermatoses of the scalp. Many studies found the foam to be less
irritating than the original formulation.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Lynn Carter, BA
- Phone Number: 301-249-0970
- Email: clinresearch@callenderskin.com
Study Contact Backup
- Name: Cherie Young, M.D.
- Phone Number: 301-249-0970
- Email: clinresearch@callenderskin.com
Study Locations
-
-
Maryland
-
Mitchellville, Maryland, United States, 20721
- Recruiting
- Callender Center for Clinical Research
-
Contact:
- Lynn Carter, BA
- Phone Number: 301-249-0970
- Email: clinresearch@callenderskin.com
-
Contact:
- Niccole Mathews
- Phone Number: 301-249-0970
- Email: clinresearch@callenderskin.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with CCCA, treated or untreated
- Score 0 - 1 on Scale/Questionnaire
- 18 years of age or older
- Women of African descent
Exclusion Criteria:
- Score > 1 on Scale/Questionnaire
- Alopecias other than CCCA, including alopecia arreata, lichen planopilaris, trichotillomania, and traction alopecia
- History of hair transplantation
- Children less than 18 years of age
- Males
- Women of non-African descent
- Pregnancy or breastfeeding. Women of childbearing age must use reliable forms of contraception (e.g., abstinence, oral contraceptives, or spermicide and condoms)
- Anti-dandruff shampoo within 30 days
- Anti-inflammatory medications such as antibiotics (doxycycline, minocycline, rifampin, etc.), steroids (oral prednisone, topical corticosteroids,etc.), NSAIDs (ibuprofen, aspirin, etc.)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Improvement of pruritis, tenderness, and pain
Time Frame: 4 months
|
4 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Absence of inflammation on biopsy
Time Frame: 4 months
|
4 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Valerie Callender, M.D., Callender Skin for Clinical Research
- Study Director: Cherie Young, M.D., Callender Center for Clinical Research
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VDC2009O
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alopecia
-
Siriraj HospitalCompletedRecalcitrant Alopecia Totalis | Recalcitrant Alopecia UniversalisThailand
-
Yale UniversityCompletedFibrosing Alopecia | Frontal Fibrosing Alopecia | Central Centrifugal Cicatricial AlopeciaUnited States
-
Aclaris Therapeutics, Inc.CompletedAlopecia Totalis (AT) | Alopecia Universalis (AU)United States
-
Yale UniversityCompletedAlopecia Areata (AA) | Alopecia Totalis (AT) | Alopecia Universalis (AU)United States
-
M.D. Anderson Cancer CenterNational Alopecia Areata FoundationActive, not recruitingAlopecia Areata | Alopecia Totalis | Alopecia Universalis | Autoimmune Hair Loss | Alopecia PartialisUnited States
-
Wake Forest University Health SciencesThe Skin of Color SocietyRecruitingCentral Centrifugal Cicatricial Alopecia (CCCA)United States
-
Erasmus Medical CenterRecruitingAutoimmune Diseases | Alopecia | Alopecia Areata | Hair Diseases | Alopecia Totalis | Alopecia Universalis | Hair Loss | Alopecia DrugsNetherlands
-
EquilliumWithdrawnAlopecia Areata | Alopecia Totalis | Alopecia Universalis
-
Lindsey BordoneWithdrawnAlopecia Areata | Alopecia Totalis | Alopecia Universalis
-
Aclaris Therapeutics, Inc.Completed
Clinical Trials on Clobetasol Propionate 0.05% Emollient Foam
-
Padagis LLCCompleted
-
Galderma R&DCompleted
-
Galderma R&DCompleted
-
Galderma R&DCompletedScalp PsoriasisCanada
-
SalvatCompleted
-
SalvatCompleted
-
Hill Dermaceuticals, Inc.Covance; Synteract, Inc.TerminatedAtopic DermatitisUnited States
-
Stiefel, a GSK CompanyGlaxoSmithKlineCompleted
-
Galderma R&DCompletedScalp PsoriasisUnited States
-
Skin Sciences, PLLCUnknownPlaque PsoriasisUnited States